RNA-based therapeutics are being designed to tackle a wide array of human ailments including cancer, diabetes, heart conditions, and infections. Yet, challenges remain in developing, customizing, manufacturing, and scaling these genetic therapies. Northpond Ventures portfolio company EnPlusOne Biosciences is enabling the future of RNA therapeutics by harnessing the power of enzymes to deliver higher quality, tailor made, and reliable RNA at scale. As the first spin-out from our alliance with the Wyss Institute at Harvard University, EnPlusOne Biosciences just announced the successful enzymatic synthesis of @Leqvio® antisense strand, a commercially approved siRNA treatment for hypercholesteremia (high-cholesterol). This breakthrough showcases the potential for enzymatic synthesis to address the needs of the rapidly expanding therapeutic siRNA market. Congratulations to Daniel Ahlstedt and the entire EnPlusOne Biosciences team on this milestone! #RNA #breakthroughtechnology #collaboration https://lnkd.in/gcsxs9rn
Northpond Ventures
Venture Capital and Private Equity Principals
Bethesda, Maryland 6,976 followers
About us
Northpond Ventures is a multi-billion-dollar science-driven venture capital firm based in Cambridge, MA; San Francisco, CA; and Bethesda, MD. Northpond has consistently been named one of the most active lead life science investors in venture industry rankings. It is deeply engaged in the academic ecosystem, having founded The Laboratory for Bioengineering Research and Innovation at the Wyss Institute at Harvard University; launched the MIT-Northpond Program – Advancing Life Science & Engineering Innovation; launched the Northpond Laboratories — Program for Research and Innovation at Stanford Medicine; and sponsored a prize for women entrepreneurs at MIT. It has led or co-led over 60 financings over the past several years and sits on the board of the vast majority of these businesses. Learn more at npv.vc.
- Website
-
http://www.npv.vc
External link for Northpond Ventures
- Industry
- Venture Capital and Private Equity Principals
- Company size
- 11-50 employees
- Headquarters
- Bethesda, Maryland
- Type
- Privately Held
- Founded
- 2018
Locations
-
Primary
Get directions
7500 Old Georgetown Rd
Suite 800
Bethesda, Maryland 20814, US
-
Get directions
4 Brattle Street, Floor 3
Cambridge, Massachusetts 02138, US
Employees at Northpond Ventures
-
Monet Uva
People Operations // Culture & Wellbeing // Admin Support // Events
-
Katie Dexter, SHRM-SCP
Sr. Director, Human Resources at Northpond Ventures
-
Ashley (Vasques) Cowher
Executive Assistant at Northpond Ventures
-
Sharon Kedar, CFA
“Daring to Dream” | Multi-Billion $ VC Co-Founder | 60+ Life Science Start Ups & Board Seats | Leading Academia Partner (Harvard, MIT, Stanford) |…
Updates
-
Totus Medicines, a Northpond Ventures portfolio company revolutionizing small molecule drug discovery, has entered into a research collaboration with Eli Lilly and Company to discover small molecule drug candidates across multiple targets. Totus Medicines’ novel platform leverages a DNA-encoded covalent library along with artificial intelligence and machine learning, enabling the company to screen billions of drug candidates against multiple targets simultaneously. Congratulations to Nassim Usman, Ph.D. and the Totus Medicines team! #innovation #collaboration #totusmedicines #drugdiscovery
Totus Medicines Announces Strategic Multi-Target Research Collaboration with Lilly. https://lnkd.in/gqT4rD5T
Totus Medicines Announces Strategic Multi-Target Research Collaboration with Lilly
globenewswire.com
-
Atrial fibrillation, or AFib, is the most common type of cardiac arrhythmia, impacting nearly 6M people in the United States. Untreated AFib causes up to 25% of strokes. Northpond Ventures portfolio company Story Health has partnered with Saint Luke's Health System's Mid America Heart Institute to codevelop and deploy an atrial fibrillation program that provides clinical decision support and virtual coaching. Leveraging digital biomarkers, AI, and virtual coaching in a platform integrated with electronic health records, physicians can see their patient’s "complete health story", ultimately enabling better care. #collaboration #innovation #storyhealth #afib
🚨 Hot off the press! Story Health and Saint Luke’s Mid America Heart Institute launch a comprehensive digital health program to support patients with atrial fibrillation. The new, co-developed AFib program delivers holistic care that magnifies specialty providers’ ability to see more patients and improve their quality of life. Read all about it.... Saint Luke's Health System #AFib #digitalhealth #innovation #cardiology https://lnkd.in/eAd4aja4
Saint Luke’s Mid America Heart Institute and Story Health Launch Comprehensive Digital Health Program to Support Patients with Atrial Fibrillation
saintlukeskc.org
-
What defines the impact venture capital can have on a startup? Our Founders, Mike Rubin, M.D., Ph.D. and Sharon Kedar, CFA discuss how Northpond Ventures is reimagining impact through the notion of co-creation, in partnership with the Wyss Institute at Harvard University. Often, game-changing science can be stuck in laboratories across the globe, stymied from reaching full potential. Now, in our 5th year of work together, The Wyss Institute at Harvard University x Northpond Ventures collaboration enables us to translate scientific discoveries from the lab to create companies, advancing science for the benefit of humanity. It is a privilege to partner with the Wyss Institute at Harvard University as we reimagine the relationship between academia and venture capital in the earliest stages of innovation in our ecosystem. Video Credit: Wyss Institute at Harvard University #collaboration #innovation #translationalscience
“Daring to Dream” | Multi-Billion $ VC Co-Founder | 60+ Life Science Start Ups & Board Seats | Leading Academia Partner (Harvard, MIT, Stanford) | Podcast Host
We know that not every company can or will make it, but might there be “early signs” that often go unnoticed? Recently Mike and I were interviewed about this topic and our innovative Wyss Institute at Harvard University x Northpond Ventures partnership. We share our thoughts in this video below, but I’d love to hear yours too. Thanks for caring enough about humanity to be following and engaging with my content. Video credit: Wyss Institute at Harvard University. (Amazing job Alexandra Jirstrand, Seth Kroll, and team) #scienceandhealth #investment #sciencebackedtech #techforgood
-
Northpond Ventures reposted this
The Wyss Institute’s alliance with Northpond Labs supports early-stage, transformative research with strong translation potential. Hear Northpond Ventures co-founders Michael Rubin, M.D., Ph.D. and Sharon Kedar, CFA explain why they decided to partner with the Wyss. Leaders of Wyss projects, Wesley Wong and Helena de Puig, and startups, Daniel Wiegand, co-founder of EnPlusOne Biosciences, also discuss how support from Northpond has helped accelerate their technologies to the market. Learn more about this collaboration: https://lnkd.in/edkgBWdr #Collaboration #VentureCapital #Biotech #Startups #TechnologyTranslation #Entrepreneurship
-
Thank you to the brilliant Dr. Don Ingber and our colleagues at the Wyss Institute at Harvard University for your relentless pursuit of revolutionary healthcare solutions! We at Northpond Ventures are grateful for your ongoing support and partnership. Tune into the latest episode of Innovate and Elevate, where Northpond Ventures Co-Founder Sharon Kedar, CFA and Wyss Institute at Harvard University Founding Director Dr. Don Ingber discuss Organ-on-a-Chip technology and its potential to transform Women’s Health. #womenshealth #innovation #translationalscience
Did you know that women were excluded from clinical trials until 1993 because of hormones and childbirth? That means conditions primarily affecting women have been incredibly understudied. What’s more, current research often uses mice a preclinical model, but how effective can that be since they do not even have a menstrual cycle? In the newest episode of Innovate and Elevate, Wyss Founding Director Don Ingber explains to Sharon Kedar, CFA of Northpond Ventures how he and his team have developed more effective Organ Chip models to understand and find therapeutics for women’s health conditions like bacterial vaginosis. #WomensHealth #OrganChips #DiseaseModels #DrugDiscovery https://lnkd.in/gSmDsN8Q
Mice Don’t Menstruate: Reimagining Women’s Health Using Organ Chips with Dr. Donald Ingber
https://wyss.harvard.edu
-
Northpond Ventures exists to advance science for the benefit of humanity. We could not do so without the collaboration of our incredible academic partners, including Dr. Donald Ingber and The Wyss Institute at Harvard University. Last week, our Co-Founder, Sharon Kedar, CFA interviewed Dr. Ingber for her podcast, Innovate and Elevate. Dr. Ingber is Founding Director of The Wyss Institute at Harvard University and Scientific Founder of Emulate, Inc., a Northpond Ventures portfolio company. In the episode, the two discuss Dr. Ingber’s breakthrough Organ Chip technology and its potential game-changing impact to Women’s Health. Thank you to Dr. Ingber, and to our friends and colleagues at The Wyss Institute at Harvard University for your ongoing support and partnership. Stay tuned for this episode of Innovate and Elevate, with season one focused on Women’s Health, available wherever you listen to podcasts. #collaboration #startedinthelab #translationalscience
“Daring to Dream” | Multi-Billion $ VC Co-Founder | 60+ Life Science Start Ups & Board Seats | Leading Academia Partner (Harvard, MIT, Stanford) | Podcast Host
How can we effectively study diseases affecting women’s reproductive organs in animal models that don’t menstruate? We can’t. Right now, mouse models are a bedrock foundation for studying women’s hormone health, from birth control to menopause. But mice don’t even have a menstrual cycle. That makes them an ineffective tool. What do we do about this? How do we develop effective research tools? I’m excited to tell you about a technology that has the potential to change the game here. It’s called Organ-on-a-Chip. If you haven’t heard about it, it’s time to catch you up. It was developed over ten years ago by the brilliant Dr. Don Ingber, the Founding Director of The Wyss Institute at Harvard University (20% of Harvard’s intellectual property comes out of the Wyss Institute). Imagine any organ in the human body. Instead of using an animal model, an Organ Chip lined with living human cells can be used to illuminate biology and do research. Even better, these Organ Chips can be used to diagnose and treat diseases. The chip itself is about the size of a USB stick. In addition to being more effective, Organ Chips are also a much more humane way to do research and drug development - reducing or eliminating the need to use animals. (Learn more about Organ Chips here: https://bit.ly/4b03LOf) Dr. Ingber is my guest for the upcoming episode of my new video podcast Innovate and Elevate. Here’s a sneak peek at the episode, where Dr. Ingber speaks about his Vagina Chip, supported by the Bill & Melinda Gates Foundation, to better understand and treat bacterial vaginosis. Please stay tuned for episode 5: Mice Don’t Menstruate: Reimagining Women’s Health Using Organ Chips with Dr. Don Ingber. #micedontmenstruate #organchips #womenshealth #innovateandelevatepodcast
-
This week, our Co-Founder, Sharon Kedar, CFA interviewed Dr. Canan Dagdeviren for her new podcast, Innovate and Elevate. Canan is an Associate Professor of Media Arts and Sciences at Massachusetts Institute of Technology and was a finalist in the Northpond Ventures/Massachusetts Institute of Technology’s Future Founders Competition for her work in changing breast cancer early detection with a wearable ultrasound bra. We are grateful to partner with Massachusetts Institute of Technology in accelerating opportunities for female founders to enhance their visibility and gain access to the venture capital ecosystem. Stay tuned for this episode of Innovate and Elevate, with season one focused on Women’s Health, available next week wherever you listen to podcasts. https://lnkd.in/e85p3nqW #breastcancerearlydetection #femalefounders #collaboration
“Daring to Dream” | Multi-Billion $ VC Co-Founder | 60+ Life Science Start Ups & Board Seats | Leading Academia Partner (Harvard, MIT, Stanford) | Podcast Host
When I first met Dr. Canan Dagdeviren two years ago, she shared with me her big hairy audacious goal of changing breast cancer early detection with a wearable ultrasound bra- I literally had chills. The idea was visionary, and in an area of medicine that would greatly benefit from better, more reliable, and more accessible screening tools. It was March 24, 2022. Canan was part of the Massachusetts Institute of Technology’s Future Founders Competition, sponsored by Northpond Ventures. (MIT has been visionary in realizing that women on STEM faculty understart companies compared to their male colleagues and have taken action to drive change.) In March 2022, Canan shared her big vision, but said that before the Future Founders Competition she was a bird with a big heart and a science wing- but could not fly without her business wing. She said the program gave her that wing. Over the past couple years, I have seen Canan and her team progress on their journey to improve breast cancer early detection with her wearable, ultrasound bra concept- with hopes of saving many, many lives. At the age of 29, Canan was inspired to drive innovation as she sat at the bedside of her aunt Fatma. It was August 2015. Her aunt was diagnosed with breast cancer at age 49 and died six months later. By her bedside, Canan created a drawing for a wearable ultrasound bra. Picture attached. Many years later, Canan is closer to making her dream a reality. Canan and I spoke in depth today about her journey and bold mission. I’m excited to share Canan’s story and updates on next week’s episode of my new Innovate and Elevate podcast- with season one focused on Women’s Health. #breastcancerearlydetection #newideas #changethegame
-
-
Northpond Ventures is pleased to continue to support Kyverna Therapeutics and its focus on developing cell therapies to treat patients suffering from autoimmune disease. We are grateful to partner with Vida Ventures, LLC, Westlake Village BioPartners®, Gilead Sciences, Bain Capital Life Sciences and RTW Investments, LP on this transformative company. Peter Maag, PhD and the entire team at Kyverna Therapeutics, congrats on today's IPO! NASDAQ: KYTX. https://lnkd.in/eDuYDXGz
-
-
Thank you to our friends and colleagues at the Wyss Institute at Harvard University team for your ongoing support and partnership! If you have not yet tuned in, last week, Sharon Kedar, CFA, Co-Founder of Northpond Ventures, launched a new podcast, Innovate and Elevate: https://lnkd.in/eR4CicsA. Season One focuses on Women's Health with the aim of helping women lead our healthiest lives. If you would like to support Innovate and Elevate, please spread the word, and subscribe to the show on Apple Podcasts, Spotify, or YouTube. #newpodcast #innovateandelevate #womenshealth #collaboration
In the inaugural episode of Innovate and Elevate, host Sharon Kedar, CFA of Northpond Ventures sits down with Kathryn Rexrode, Chief of the Chief of the Division of Women's Health at Brigham and Women's Hospital, Professor of Medicine at Harvard Medical School, and Wyss Visiting Scholar. The two discuss Kathryn's non-linear career path and the importance of rejecting a scarcity mindset and supporting other women professionally. The two originally met at a Wyss Institute Women's Health Catalyst event last year, where they were both panelists discussing women's health and leadership. #Podcast #Collaboration #WomensHealth #Partnerships https://lnkd.in/eddpcHUN
Treat Your Body As If You Were Pregnant with Dr. Kathryn M. Rexrode — Innovate and Elevate Podcast
innovateandelevatepodcast.com